Positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of talazoparib, an oral poly ADP-ribose polymerase (PARP) inhibitor in combination with enzalutamide, an androgen receptor pathway inhibitor, for metastatic castration-resistant prostate cancer (mCRPC) are to be shared with global health authorities to potentially update the talazoparib approved label. ...